Correction: Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials

Bibliographic Details
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2011-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072428/?tool=EBI

Correction: Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials.
by: Ansar A. Pathan, et al.
Published: (2011-01-01)

Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials
by: Pathan, A, et al.
Published: (2007)

Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials.
by: Pathan, A, et al.
Published: (2007)

Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: different boosting intervals and implications for efficacy trials.
by: Ansar A Pathan, et al.
Published: (2007-10-01)

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.
by: McShane, H, et al.
Published: (2004)

Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis.
by: Tchilian, E, et al.
Published: (2009)

Erratum: Immunogenicity and protective efficacy of prime-boost regimens with recombinant δureC hly+ Mycobacterium bovis BCG and modified Vaccinia virus Ankara expressing M. tuberculosis antigen 85A against murine tuberculosis
by: Tchilian, E, et al.
Published: (2011)

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
by: McConkey, S, et al.
Published: (2003)

Immunogenicity and Protective Efficacy of Prime-Boost Regimens with Recombinant Delta ureC hly(+) Mycobacterium bovis BCG and Modified Vaccinia Virus Ankara Expressing M. tuberculosis Antigen 85A against Murine Tuberculosis, (vol 77, pg 630, 2009)
by: Tchilian, E, et al.
Published: (2011)

Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen.
by: Maria L Knudsen, et al.
Published: (2015-01-01)

Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
by: Rosario, M, et al.
Published: (2010)

Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A
by: Stylianou, E, et al.
Published: (2015)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A
Published: (2011-01-01)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
by: Kathryn T. Whelan, et al.
Published: (2011-01-01)

Protection against highly pathogenic SIV by BCG-SIV recombinant priming and attenuated replicating vaccinia-SIV recombinant boosting
by: Zhang X, et al.
Published: (2012-09-01)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
by: Whelan, K, et al.
Published: (2009)

Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein.
by: Walther, M, et al.
Published: (2006)

Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
by: Goonetilleke, N, et al.
Published: (2003)

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.
by: Schneider, J, et al.
Published: (1998)

Mucosal immunization with PLGA-microencapsulated DNA primes a SIV-specific CTL response revealed by boosting with cognate recombinant modified vaccinia virus Ankara.
by: Sharpe, S, et al.
Published: (2003)

Improved Host Range Selection for Recombinant Modified Vaccinia Virus Ankara
by: Caroline Staib, et al.
Published: (2003-04-01)

A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees.
by: Schneider, J, et al.
Published: (2001)

Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant
by: Ning Yang, et al.
Published: (2022-10-01)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
by: Mcshane, H
Published: (2008)

Correction: MVA.85A Boosting of BCG and an Attenuated, Deficient Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques.
by: Frank A. W. Verreck, et al.
Published: (2011-01-01)

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.
by: Mcshane, H, et al.
Published: (2001)

Immunogenicity and Protective Efficacy of a Novel Recombinant BCG Strain Overexpressing Antigens Ag85A and Ag85B
by: Chun Wang, et al.
Published: (2012-01-01)

Therapeutic vaccination against hepatitis B virus using heterolgous prime boost strategy with DNA and modified vaccinia virus ankara vectors
by: McConkey, S, et al.
Published: (2003)

Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants.
by: Gavin Churchyard, et al.
Published: (2016-01-01)

Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara.
by: Smith, C, et al.
Published: (2005)

Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro.
by: Dorrell, L, et al.
Published: (2000)

Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models.
by: Dégano, P, et al.
Published: (1999)

Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses.
by: Reyes-Sandoval, A, et al.
Published: (2010)

Preferential targeting of conserved Gag regions after vaccination with a heterologous DNA prime Modified Vaccinia Ankara boost HIV vaccine regime
by: Bauer A, et al.
Published: (2012-09-01)

Correction: Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA).
by: Matthew G. Cottingham, et al.
Published: (2011-01-01)

Correction: Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA)
Published: (2011-01-01)

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
by: Mcshane, H, et al.
Published: (2005)

New approaches for improving the immunogenicity of modified vaccinia virus Ankara as a recombinant vaccine vector
by: Alharbi, N
Published: (2014)

Vaccination with Combination DNA and Virus-Like Particles Enhances Humoral and Cellular Immune Responses upon Boost with Recombinant Modified Vaccinia Virus Ankara Expressing Human Immunodeficiency Virus Envelope Proteins
by: Sailaja Gangadhara, et al.
Published: (2017-12-01)

Clinical development of Modified Vaccinia virus Ankara vaccines.
by: Gilbert, S
Published: (2013)

Correction: Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials

Similar Items

Similar Items